Quantcast

Latest Decipher Stories

2014-09-17 20:22:13

Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after surgery, improving treatment decision-making SAN FRANCISCO, Sept. 17, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that data featured in an oral presentation at the 56(th) Annual Meeting of the American Society for Radiation Oncology (ASTRO) demonstrates convincing evidence of the...

2014-09-15 20:22:10

Data presented at American Society for Radiology (ASTRO) Annual Meeting in San Francisco SAN FRANCISCO, Sept. 15, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new studies presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrate the ability of its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting aggressiveness of prostate cancer, to influence treatment decisions and improve patient outcomes for...

2014-06-16 08:28:19

SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide diagnostic laboratory testing services. GenomeDx, which discovered and developed the Decipher® Prostate Cancer Classifier, will provide laboratory services, making the Decipher test available to members of the Prime Health network, which includes 9 million covered lives. Prime Health payors...

2014-05-20 16:26:25

Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, was able to identify patients that may be spared of radiation therapy after prostate surgery who would have been otherwise classified as high risk based on current clinical practice guidelines. In a separate study,...

2014-05-16 08:26:14

SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical practitioners to use and understand genomic information about prostate cancer and how it can impact their clinical practice. It offers physicians the opportunity to explore Decipher clinical data on interactive graphs, engage in hands-on exploration of clinical use scenarios and learn more...

2014-05-14 08:30:35

Two new clinical utility studies of Decipher published in BJU International and Current Medical Research and Opinion SAN DIEGO, May 14, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new clinical utility studies demonstrating that Decipher® Prostate Cancer Classifier significantly changed treatment decisions and increased confidence in treatment decision-making for men considering adjuvant therapy following prostate surgery. The studies are being published...

2014-05-08 08:32:48

SAN DIEGO, May 8, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that the company's Decipher® Prostate Cancer Classifier will be featured in multiple sessions during the American Urological Association (AUA) Annual Meeting taking place May 16-21 in Orlando, FL. Two data presentations will detail validation studies supporting the use of Decipher to predict risk of metastasis in men following prostate surgery. Decipher has also been included in independent CME and educational...

2014-04-18 15:41:30

Researchers propose classification system revolutionizing communication of chromosomal abnormalities for research and clinical settings When talking about genetic abnormalities at the DNA level that occur when chromosomes swap, delete or add parts, there is an evolving communication gap both in the science and medical worlds, leading to inconsistencies in clinical and research reports. Now a study by researchers at Brigham and Women's Hospital (BWH) proposes a new classification system...

2014-02-03 08:27:25

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher(®) prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher( )prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related